CVE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free MDP Stock Alerts C$7.75 -0.40 (-4.91%) (As of 06/16/2021) Add Compare Share Share Today's RangeC$7.70▼C$8.1450-Day RangeC$7.75▼C$7.7552-Week RangeC$2.80▼C$9.75Volume40,981 shsAverage Volume68,619 shsMarket CapitalizationC$148.54 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.18 Stock AnalysisStock Analysis Get Medexus Pharmaceuticals alerts: Email Address Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Medexus Pharmaceuticals Stock (CVE:MDP)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.Read More MDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDP Stock News HeadlinesFebruary 13, 2024 | au.finance.yahoo.comMedexus Pharmaceuticals Inc (P731.BE)February 10, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…January 30, 2024 | finance.yahoo.comMedexus Schedules Third Fiscal Quarter 2024 Conference CallNovember 30, 2023 | finance.yahoo.comBoasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock?November 8, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 MillionNovember 1, 2023 | finance.yahoo.comMedexus Schedules Second Fiscal Quarter 2024 Conference CallOctober 16, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDP.DBMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 11, 2023 | finance.yahoo.comMedexus Pharmaceuticals' (TSE:MDP) earnings growth rate lags the 131% return delivered to shareholdersOctober 6, 2023 | finance.yahoo.comMedexus Announces Closing of C$10 Million Bought-Deal Public OfferingSeptember 15, 2023 | finance.yahoo.comShareholders May Be More Conservative With Medexus Pharmaceuticals Inc.'s (TSE:MDP) CEO Compensation For NowAugust 31, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 16.36% to 3.18August 23, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Wednesday (MDP)August 19, 2023 | finance.yahoo.comHere's Why We Think Medexus Pharmaceuticals (TSE:MDP) Is Well Worth WatchingJuly 13, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Gets a Buy Rating from Stifel NicolausJune 22, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Echelon Wealth PartnersJune 21, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023June 21, 2023 | finance.yahoo.comMedexus Generates Record Revenue of US$108.1 Million in Fiscal Year 2023June 13, 2023 | finance.yahoo.comMedexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023May 9, 2023 | finance.yahoo.comMedexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade GliomaMay 3, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Tuesday (MDP)April 18, 2023 | finance.yahoo.comMedexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Thursday (MDP)April 13, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Wednesday (MDP)April 12, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Tuesday (MDP)April 7, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Thursday (MDP)See More Headlines Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone514-762-2626FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetC$3.18 High Stock Price TargetC$4.00 Low Stock Price TargetC$2.35 Potential Upside/Downside-59.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio9.23 P/E Growth-2153Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1,174.36 Current Ratio1.19 Quick Ratio0.74 Sales & Book Value Annual SalesC$108.29 million Price / Sales1.37 Cash FlowC$0.62 per share Price / Cash Flow12.46 Book ValueC$0.38 per share Price / Book20.50Miscellaneous Outstanding Shares19,167,000Free FloatN/AMarket CapC$148.54 million OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Roland BoivinChief Financial OfficerMr. Bill PoncySr. VP of Commercial Operations - United StatesMr. Brian PetersVP of Sales & Marketing - United StatesMs. Tina Byers CFAExec. of Investor RelationsMr. Michael PineSr. VP of Bus. Devel. & StrategyMr. Michael David Adelman (Age 50)Gen. Mang., U.S. Operations More ExecutivesKey CompetitorsCardiol TherapeuticsTSE:CRDLHLS TherapeuticsTSE:HLSBioSyentCVE:RXLeaf MobileTSE:LEAFGreen Organic DutchmanTSE:TGODView All CompetitorsInsidersBenoit GravelBought 3,200 shares on 2/13/2024Total: C$5,408.00 ($1.69/share) MDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medexus Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares. View MDP analyst ratings or view top-rated stocks. What is Medexus Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 12-month target prices for Medexus Pharmaceuticals' stock. Their MDP share price targets range from C$2.35 to C$4.00. On average, they predict the company's share price to reach C$3.18 in the next year. This suggests that the stock has a possible downside of 59.0%. View analysts price targets for MDP or view top-rated stocks among Wall Street analysts. How have MDP shares performed in 2024? Medexus Pharmaceuticals' stock was trading at C$7.75 on January 1st, 2024. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75. View the best growth stocks for 2024 here. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN). How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:MDP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.